{"slug":"cns","as_of":"2026-10-23","verified_at":"2026-10-23","languages":{"zh":{"title":"台灣中樞神經新藥公司與管線總表","summary":[{"text":"截至2026年10月23日，本表收錄7家台灣公司的神經系統與疼痛藥物或細胞治療項目，包含臨床前、已完成及已終止的試驗。","source_urls":["https://clinicaltrials.gov/api/v2/studies/NCT05198323","https://www.foreseepharma.com/en/rd/overview","https://clinicaltrials.gov/api/v2/studies/NCT05413655","https://clinicaltrials.gov/api/v2/studies/NCT07222748","https://clinicaltrials.gov/api/v2/studies/NCT04088149","https://clinicaltrials.gov/api/v2/studies/NCT02261519","https://clinicaltrials.gov/api/v2/studies/NCT04434768","https://www.gwoxi.com/product-2.html"]},{"text":"所選項目涵蓋急性與慢性腦中風、阿茲海默症、思覺失調症及術後疼痛；台微體TLC590登錄為第3期且不再收案，心悅NaBen所選試驗則登錄為終止。","source_urls":["https://clinicaltrials.gov/api/v2/studies/NCT05198323","https://www.foreseepharma.com/en/rd/overview","https://clinicaltrials.gov/api/v2/studies/NCT05413655","https://clinicaltrials.gov/api/v2/studies/NCT07222748","https://clinicaltrials.gov/api/v2/studies/NCT04088149","https://clinicaltrials.gov/api/v2/studies/NCT02261519","https://clinicaltrials.gov/api/v2/studies/NCT04434768","https://www.gwoxi.com/product-2.html"]}],"undisclosed":"本表為經來源核對的選列，非完整產業清冊或仍活躍試驗名單；疼痛項目可包括周邊局部止痛。登錄狀態保留各試驗最後更新日；試驗核准、完成與產品上市分別標示。"},"en":{"title":"Taiwan CNS Drug Companies and Pipelines","summary":[{"text":"As of October 23, 2026, this table includes neurological and pain drug or cell-therapy programs at 7 Taiwan companies, including preclinical programs and completed or terminated trials.","source_urls":["https://clinicaltrials.gov/api/v2/studies/NCT05198323","https://www.foreseepharma.com/en/rd/overview","https://clinicaltrials.gov/api/v2/studies/NCT05413655","https://clinicaltrials.gov/api/v2/studies/NCT07222748","https://clinicaltrials.gov/api/v2/studies/NCT04088149","https://clinicaltrials.gov/api/v2/studies/NCT02261519","https://clinicaltrials.gov/api/v2/studies/NCT04434768","https://www.gwoxi.com/product-2.html"]},{"text":"Selected indications include acute and chronic stroke, Alzheimer disease, schizophrenia and postsurgical pain; the selected TLC590 trial is Phase 3 and active, not recruiting, while the selected SyneuRx NaBen trial is terminated.","source_urls":["https://clinicaltrials.gov/api/v2/studies/NCT05198323","https://www.foreseepharma.com/en/rd/overview","https://clinicaltrials.gov/api/v2/studies/NCT05413655","https://clinicaltrials.gov/api/v2/studies/NCT07222748","https://clinicaltrials.gov/api/v2/studies/NCT04088149","https://clinicaltrials.gov/api/v2/studies/NCT02261519","https://clinicaltrials.gov/api/v2/studies/NCT04434768","https://www.gwoxi.com/product-2.html"]}],"undisclosed":"This is a verified selection rather than an industry census or a list of active trials. Pain programs may act locally in the periphery. Registry statuses retain each study update date; trial authorization, completion and product approval are distinct."}},"companies":[{"company":"順藥","company_en":"Lumosa Therapeutics","ticker":"6535","product":"LT3001（併用血管內取栓，LT3001-203）","product_en":"LT3001 with endovascular thrombectomy (LT3001-203)","indication":"接受血管內取栓的急性缺血性腦中風","indication_en":"Acute ischemic stroke undergoing endovascular thrombectomy","stage":"第2期；ACTIVE_NOT_RECRUITING（進行中、不再收案；NCT05198323）","stage_en":"Phase 2; ACTIVE_NOT_RECRUITING (NCT05198323)","as_of":"2026-08-31","source":"https://clinicaltrials.gov/api/v2/studies/NCT05198323","quote":"ACTIVE_NOT_RECRUITING","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"順天醫藥生技股份有限公司","catalyst":null,"date_basis":"ClinicalTrials.gov最後公開更新2026-08-31；只描述所選LT3001-203試驗。"},{"company":"逸達","company_en":"Foresee Pharmaceuticals","ticker":"6576","product":"FP-018（cariprazine長效注射劑）","product_en":"FP-018 (cariprazine long-acting injection)","indication":"思覺失調症與雙極性情感疾患","indication_en":"Schizophrenia and bipolar disorder","stage":"臨床前；公司現行研發頁列為preclinical-stage","stage_en":"Preclinical; classified as preclinical-stage on the current company R&D page","as_of":"2026-10-23","source":"https://www.foreseepharma.com/en/rd/overview","quote":"preclinical-stage","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"逸達生物科技股份有限公司","catalyst":null,"date_basis":"無日期現行研發頁明示FP-018為臨床前；as_of為查閱日。"},{"company":"科懋","company_en":"Excelsior Biopharma","ticker":"6496","product":"EX039（EX-039）","product_en":"EX039 (EX-039)","indication":"輕度阿茲海默症；合併乙醯膽鹼酯酶抑制劑","indication_en":"Mild Alzheimer disease; add-on to acetylcholinesterase inhibitors","stage":"第2期；RECRUITING（登錄招募中；NCT05413655）","stage_en":"Phase 2; RECRUITING (NCT05413655)","as_of":"2025-02-26","source":"https://clinicaltrials.gov/api/v2/studies/NCT05413655","quote":"RECRUITING","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"科懋生物科技股份有限公司","catalyst":null,"date_basis":"ClinicalTrials.gov最後公開更新2025-02-26；2026-10-23重新讀取，保留登錄原日期及狀態。","product_source":"https://mopsov.twse.com.tw/nas/STR/649620251216M001.pdf","product_quote":"EX-039","product_as_of":"2025-12-16"},{"company":"台微體（2021年下市）","company_en":"Taiwan Liposome Company (delisted in 2021)","ticker":"4152","product":"TLC590（ropivacaine長效局部注射劑）","product_en":"TLC590 (long-acting local ropivacaine injection)","indication":"拇趾外翻切除術後疼痛","indication_en":"Postsurgical pain following bunionectomy","stage":"第3期；ACTIVE_NOT_RECRUITING（進行中、不再收案；NCT07222748）","stage_en":"Phase 3; ACTIVE_NOT_RECRUITING (NCT07222748)","as_of":"2026-07-02","source":"https://clinicaltrials.gov/api/v2/studies/NCT07222748","quote":"ACTIVE_NOT_RECRUITING","company_source":"https://www.tlcbio.com/en/about/us","company_quote":"ticker: 4152","catalyst":null,"product_source":"https://www.tlcbio.com/en/pipeline/Orthopedics/TLC590","product_quote":"ropivacaine","product_as_of":"2026-10-23","date_basis":"ClinicalTrials.gov最後公開更新2026-07-02；本列為疼痛領域之周邊局部止痛研發，非宣稱中樞作用機轉。4152為歷史代號，2021年下櫃。"},{"company":"國璽幹細胞","company_en":"Gwo Xi Stem Cell Applied Technology","ticker":"6704","product":"思益優 GXNPC1（自體脂肪來源幹細胞）","product_en":"GXNPC1 (autologous adipose-derived stem cells)","indication":"慢性腦中風","indication_en":"Chronic stroke","stage":"第2期COMPLETED（NCT04088149）；2026年8月核准執行第3期試驗","stage_en":"Phase 2 COMPLETED (NCT04088149); Phase 3 trial authorized in August 2026","as_of":"2024-09-19","source":"https://clinicaltrials.gov/api/v2/studies/NCT04088149","quote":"COMPLETED","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R","company_quote":"國璽幹細胞應用技術股份有限公司","catalyst":null,"product_source":"https://www.gwoxi.com/product-2.html","product_quote":"衛生福利部核准執行第三期臨床試驗","product_as_of":"2026-10-23","date_basis":"所選第2期登錄最後更新2024-09-19；公司產品頁另載2026年8月第3期試驗許可。許可不等於已開始收案，未將第2期登錄狀態套到第3期。"},{"company":"心悅生醫","company_en":"SyneuRx International (Taiwan)","ticker":"6575 (former emerging-stock ticker; terminated 2023)","product":"NaBen（苯甲酸鈉；SNR-04）","product_en":"NaBen (sodium benzoate; SNR-04)","indication":"成人思覺失調症之加成治療","indication_en":"Add-on treatment for schizophrenia in adults","stage":"第2b/3期；TERMINATED（因商業策略終止；NCT02261519）","stage_en":"Phase 2b/3; TERMINATED due to commercial strategy (NCT02261519)","as_of":"2024-05-24","source":"https://clinicaltrials.gov/api/v2/studies/NCT02261519","quote":"TERMINATED","company_source":"https://www.tpex.org.tw/storage/eb_data/11201/11201000662.html","company_quote":"心悅生醫股份有限公司","catalyst":null,"date_basis":"ClinicalTrials.gov最後公開更新2024-05-24；whyStopped為due to commercial strategy。6575為原興櫃代號，櫃買中心公告2023-01-27終止興櫃買賣。"},{"company":"長聖","company_en":"Ever Supreme Bio Technology","ticker":"6712","product":"UMSC01（異體臍帶間質幹細胞）","product_en":"UMSC01 (allogeneic umbilical cord mesenchymal stem cells)","indication":"急性缺血性腦中風","indication_en":"Acute ischemic stroke","stage":"第1期；COMPLETED（已完成；NCT04434768）","stage_en":"Phase 1; COMPLETED (NCT04434768)","as_of":"2026-09-23","source":"https://clinicaltrials.gov/api/v2/studies/NCT04434768","quote":"COMPLETED","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"長聖國際生技股份有限公司","catalyst":null,"date_basis":"ClinicalTrials.gov最後公開更新2026-09-23；本列只描述急性腦中風第1期，不套用其他UMSC01適應症試驗階段。"}],"scope":{"not_exhaustive":true,"coverage":"One selected program per company, including preclinical, completed and terminated programs; neurological cell therapies and locally acting postsurgical pain drugs are included. Historical tickers are identified.","stage_basis":"Stages reflect the cited source and its stated date. An undated live page uses the access date; source review does not make an old status a newly reported event.","count_basis":"7 distinct companies, not 7 active clinical programs. A Phase 3 trial clearance is not a recruitment-status claim."}}